Abstract
In a close future, PSMA-PET will be a key tool in the management at all stages of patients with prostatic adenocarcinoma. It will be complementary to MRI for the locoregional extension and for the delineation of tumor volumes for external beam radiotherapy. It will supplant choline-PET and standard imaging by CT and bone scintigraphy for both initial staging and restaging. For metastatic diseases, it will select patients for radionuclide therapy with PSMA ligands radiolabeled with electron emitters isotopes and will be able to evaluate the effectiveness. A flare-up effect of hormone therapy seems to exist and evaluation of the androgenic blockade by PET-PSMA should be done with caution. Bombesin antagonists are currently in clinical development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
